NextCure Analyst Ratings
NextCure Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/08/2023 | 311.76% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 08/04/2023 | 252.94% | Needham | → $6 | Reiterates | Buy → Buy |
| 05/05/2023 | 252.94% | Needham | → $6 | Reiterates | → Buy |
| 03/03/2023 | 252.94% | Needham | → $6 | Reiterates | → Buy |
| 11/04/2022 | — | Ladenburg Thalmann | Downgrades | Buy → Neutral | |
| 11/04/2022 | 252.94% | Needham | $12 → $6 | Maintains | Buy |
| 11/04/2022 | 252.94% | Piper Sandler | $13 → $6 | Maintains | Overweight |
| 08/23/2022 | 782.35% | Truist Securities | $19 → $15 | Maintains | Buy |
| 05/23/2022 | 664.71% | Piper Sandler | $21 → $13 | Maintains | Overweight |
| 03/01/2022 | 841.18% | Ladenburg Thalmann | → $16 | Initiates Coverage On | → Buy |
| 11/05/2021 | 723.53% | Needham | $30 → $14 | Maintains | Buy |
| 03/05/2021 | 1017.65% | Truist Securities | $13 → $19 | Upgrades | Hold → Buy |
| 01/15/2021 | 488.24% | B of A Securities | $13 → $10 | Downgrades | Neutral → Underperform |
| 07/16/2020 | 900% | Benchmark | → $17 | Upgrades | Hold → Buy |
| 07/14/2020 | 1488.24% | BTIG | $61 → $27 | Maintains | Buy |
| 07/13/2020 | 664.71% | SunTrust Robinson Humphrey | $78 → $13 | Downgrades | Buy → Hold |
| 06/01/2020 | — | Benchmark | Downgrades | Buy → Hold | |
| 05/08/2020 | 3076.47% | Morgan Stanley | $58 → $54 | Maintains | Overweight |
| 04/15/2020 | 3311.76% | Morgan Stanley | $55 → $58 | Maintains | Overweight |
| 03/02/2020 | 4605.88% | Roth Capital | → $80 | Initiates Coverage On | → Buy |
| 01/13/2020 | 4488.24% | SunTrust Robinson Humphrey | → $78 | Initiates Coverage On | → Buy |
| 12/17/2019 | 3135.29% | Morgan Stanley | $52 → $55 | Maintains | Overweight |
| 11/26/2019 | 3488.24% | BTIG | → $61 | Initiates Coverage On | → Buy |
| 11/13/2019 | 2958.82% | Morgan Stanley | $33 → $52 | Maintains | Overweight |
| 11/12/2019 | 5135.29% | B of A Securities | $92 → $89 | Reiterates | → Buy |
| 09/09/2019 | 2488.24% | B of A Securities | $27 → $44 | Reiterates | → Buy |
| 09/05/2019 | 3076.47% | Piper Sandler | $26 → $54 | Maintains | Overweight |
| 08/13/2019 | 1841.18% | Morgan Stanley | $25 → $33 | Maintains | Overweight |
| 07/09/2019 | — | B of A Securities | Initiates Coverage On | → Buy | |
| 06/03/2019 | 1370.59% | Morgan Stanley | → $25 | Initiates Coverage On | → Overweight |
| 06/03/2019 | 1429.41% | Piper Sandler | → $26 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023/08/08 | 311.76% | HC Wainwright公司 | →$7 | 开始承保 | →购买 |
| 08/04/2023 | 252.94% | 李约瑟 | →$6 | 重申 | 购买→购买 |
| 05/05/2023 | 252.94% | 李约瑟 | →$6 | 重申 | →购买 |
| 03/03/2023 | 252.94% | 李约瑟 | →$6 | 重申 | →购买 |
| 11/04/2022 | - | 拉登堡·塔尔曼 | 评级下调 | 购买→中性 | |
| 11/04/2022 | 252.94% | 李约瑟 | $12→$6 | 维护 | 买 |
| 11/04/2022 | 252.94% | 派珀·桑德勒 | $13→$6 | 维护 | 超重 |
| 2022年08月23日 | 782.35% | Truist证券 | $19→$15 | 维护 | 买 |
| 2022年05月23日 | 664.71% | 派珀·桑德勒 | $21→$13 | 维护 | 超重 |
| 03/01/2022 | 841.18% | 拉登堡·塔尔曼 | →$16 | 开始承保 | →购买 |
| 2021年11月05日 | 723.53% | 李约瑟 | $30→$14 | 维护 | 买 |
| 03/05/2021 | 1017.65% | Truist证券 | $13→$19 | 升级 | 持有→购买 |
| 2021/01/15 | 488.24% | B of A证券 | $13→$10 | 评级下调 | 中性→表现不佳 |
| 07/16/2020 | 900% | 基准 | →$17 | 升级 | 持有→购买 |
| 07/14/2020 | 1488.24% | BTIG | $61→$27 | 维护 | 买 |
| 07/13/2020 | 664.71% | SunTrust Robinson Humphrey | $78→$13 | 评级下调 | 购买→Hold |
| 06/01/2020 | - | 基准 | 评级下调 | 购买→Hold | |
| 05/08/2020 | 3076.47% | 摩根士丹利 | $58→$54 | 维护 | 超重 |
| 04/15/2020 | 3311.76% | 摩根士丹利 | $55→$58 | 维护 | 超重 |
| 03/02/2020 | 4605.88% | 罗斯资本 | →$80 | 开始承保 | →购买 |
| 2020/01/13 | 4488.24% | SunTrust Robinson Humphrey | →$78 | 开始承保 | →购买 |
| 2019年12月17日 | 3135.29% | 摩根士丹利 | $52→$55 | 维护 | 超重 |
| 2019年11月26日 | 3488.24% | BTIG | →$61 | 开始承保 | →购买 |
| 2019年11月13日 | 2958.82% | 摩根士丹利 | $33→$52 | 维护 | 超重 |
| 2019年11月12日 | 5135.29% | B of A证券 | $92→$89 | 重申 | →购买 |
| 2019年09月09日 | 2488.24% | B of A证券 | $27→$44 | 重申 | →购买 |
| 2019年05月09日 | 3076.47% | 派珀·桑德勒 | $26→$54 | 维护 | 超重 |
| 2019年08月13日 | 1841.18% | 摩根士丹利 | $25→$33 | 维护 | 超重 |
| 2019年07月09日 | - | B of A证券 | 开始承保 | →购买 | |
| 2019年03月06日 | 1370.59% | 摩根士丹利 | →$25 | 开始承保 | →超重 |
| 2019年03月06日 | 1429.41% | 派珀·桑德勒 | →$26 | 开始承保 | →超重 |
What is the target price for NextCure (NXTC)?
NextCure的目标价是多少？
The latest price target for NextCure (NASDAQ: NXTC) was reported by HC Wainwright & Co. on August 8, 2023. The analyst firm set a price target for $7.00 expecting NXTC to rise to within 12 months (a possible 311.76% upside). 8 analyst firms have reported ratings in the last year.
HC Wainwright&Co.于2023年8月8日报道了NextCure(纳斯达克代码：NXTC)的最新目标价。这家分析公司将目标价定为7美元，预计NXTC将在12个月内上涨至(可能上涨311.76%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for NextCure (NXTC)?
分析师对NextCure的最新评级是多少？
The latest analyst rating for NextCure (NASDAQ: NXTC) was provided by HC Wainwright & Co., and NextCure initiated their buy rating.
纳斯达克(代码：NXTC)的最新分析师评级由HC Wainwright&Co.提供，NextCure启动了他们的买入评级。
When is the next analyst rating going to be posted or updated for NextCure (NXTC)?
NextCure的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on August 8, 2023 so you should expect the next rating to be made available sometime around August 8, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与NextCure的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。NextCure的上一次评级是在2023年8月8日提交的，所以你应该预计下一次评级将在2024年8月8日左右提供。
Is the Analyst Rating NextCure (NXTC) correct?
分析师对NextCure的评级正确吗？
While ratings are subjective and will change, the latest NextCure (NXTC) rating was a initiated with a price target of $0.00 to $7.00. The current price NextCure (NXTC) is trading at is $1.70, which is within the analyst's predicted range.
虽然评级是主观的，而且会发生变化，但最新的NextCure(NXTC)评级是以0.00美元至7.00美元的目标价启动的。目前，NextCure的交易价格为1.70美元，在分析师的预测范围内。